Analyst Price Targets — ENGN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 18, 2026 6:37 am | Judah Frommer | Morgan Stanley | $3.00 | $1.74 | StreetInsider | Morgan Stanley Downgrades Engene Holdings Inc. (ENGN) to Underweight |
| June 16, 2026 10:09 am | Andres Maldonado | H.C. Wainwright | $4.00 | $1.77 | StreetInsider | Engene Holdings Inc. (ENGN) PT Lowered to $4 at H.C. Wainwright |
| May 14, 2026 12:34 pm | — | UBS | $2.00 | $1.63 | TheFly | enGene price target lowered to $2 from $9 at UBS |
| May 8, 2026 11:47 am | Market Perform | Leerink Partners | $2.00 | $1.72 | TheFly | enGene downgraded to Market Perform from Outperform at Leerink |
| May 8, 2026 9:10 am | — | Raymond James | $4.00 | $1.72 | TheFly | enGene downgraded to Outperform from Strong Buy at Raymond James |
| May 8, 2026 9:09 am | Allison Bratzel | Piper Sandler | $4.00 | $1.72 | TheFly | enGene downgraded to Neutral from Overweight at Piper Sandler |
| May 8, 2026 12:55 am | — | Wells Fargo | $2.00 | $1.72 | TheFly | enGene downgraded to Equal Weight from Overweight at Wells Fargo |
| March 9, 2026 2:16 pm | Sean McCutcheon | Raymond James | $27.00 | $7.79 | StreetInsider | Raymond James Reiterates Strong Buy Rating on Engene Holdings Inc. (ENGN) following Q1 results |
| January 30, 2026 9:58 am | — | Jefferies | $28.00 | $10.27 | TheFly | enGene initiated with a Buy at Jefferies |
| December 3, 2025 11:43 am | Andres Maldonado | H.C. Wainwright | $25.00 | $7.86 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Engene Holdings Inc. (ENGN) |
Latest News for ENGN
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential regulatory milestones and to support commercial readiness for detalimogene voraplasmid (“detalimogene”) if approved. Detalimogene is being evaluated in the ongoing, open-label,…
CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and enhance membrane protein function, today announced the appointment of Constantine Chinoporos as Executive Chairman of the company's board of directors, effective immediately.
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced its financial results for the second quarter ended April 30, 2026, and provided clinical and corporate updates. “Feedback from the urology community on the emerging detalimogene without surfactant profile, presented at the AUA meeting in May,…
LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of enGene Therapeutics Inc. ("enGene" or "the Company") (NASDAQ: ENGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information…
LOS ANGELES, June 8, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of enGene Therapeutics Inc. ("enGene" or "the Company") (NASDAQ: ENGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ENGN.
U.S. House Trading
No House trades found for ENGN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.